About nemaura medical inc - NMRD
Nemaura Medical, Inc. operates as a holding company. The firm engages in the provision of medical device research. It manufactures and commercializes glucose monitoring system, named sugarBEAT. The sugarBEAT consists of a disposable adhesive skin-patch connected to a rechargeable wireless transmitter that displays glucose readings at regular five minute intervals with the use of a mobile app. The company was founded by Dewan Fazlul Hoque Chowdhury on December 24, 2013 and is headquartered in New York, NY.
NMRD At a Glance
Nemaura Medical, Inc.
57 West 57th Street
New York, New York 10019
| Phone | 1-646-416-8000 | Revenue | 77.04K | |
| Industry | Medical Specialties | Net Income | -14,143,735.00 | |
| Sector | Health Technology | Employees | 38 | |
| Fiscal Year-end | 03 / 2024 | |||
| View SEC Filings |
NMRD Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 289.003 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.085 |
| Enterprise Value to Sales | 417.826 |
| Total Debt to Enterprise Value | 0.622 |
NMRD Efficiency
| Revenue/Employee | 2,027.474 |
| Income Per Employee | -372,203.553 |
| Receivables Turnover | 0.188 |
| Total Asset Turnover | 0.004 |
NMRD Liquidity
| Current Ratio | 0.608 |
| Quick Ratio | 0.529 |
| Cash Ratio | 0.454 |
NMRD Profitability
| Gross Margin | -2,492.821 |
| Operating Margin | -10,803.774 |
| Pretax Margin | -18,357.997 |
| Net Margin | -18,357.997 |
| Return on Assets | -77.151 |
| Return on Equity | N/A |
| Return on Total Capital | -172.15 |
| Return on Invested Capital | N/A |
NMRD Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 243.796 |
| Total Debt to Total Assets | 137.539 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 37.581 |